% ============================================================================
% CONSTRAINT STORY: crispr_genomic_rewrite_2026
% ============================================================================
% Version: 1.0 (Deferential Realism Core + Directionality + Boltzmann + Network)
% Logic: 6.0 (Indexed Tuple P,T,E,S + Sigmoid f(d) + Coupling + Purity + Network)
% Generated: 2026-02-26
% Status: [ACTIVE]
% ============================================================================

:- module(constraint_crispr_genomic_rewrite_2026, []).

:- use_module(constraint_indexing).
:- use_module(domain_priors).
:- use_module(narrative_ontology).

% --- Constraint Identity Rule (DP-001: ε-Invariance) ---
% Each constraint story must have a single, stable base extractiveness (ε).
% If changing the observable used to evaluate this constraint would change ε,
% you are looking at two distinct constraints. Write separate .pl files for
% each, link them with affects_constraint/2, and document the relationship
% in both files' narrative context sections.
%
% The context tuple is CLOSED at arity 4: (P, T, E, S).
% Do not add measurement_basis, beneficiary/victim, or any other arguments.
% Linter Rule 23 enforces context/4.
%
% See: epsilon_invariance_principle.md

% --- Namespace Hooks (Required for loading) ---
:- multifile
    domain_priors:base_extractiveness/2,
    domain_priors:suppression_score/2,
    domain_priors:theater_ratio/2,
    domain_priors:requires_active_enforcement/1,
    narrative_ontology:has_sunset_clause/1,
    narrative_ontology:interval/3,
    narrative_ontology:measurement/5,
    narrative_ontology:constraint_metric/3,
    narrative_ontology:constraint_beneficiary/2,
    narrative_ontology:constraint_victim/2,
    narrative_ontology:constraint_claim/2,
    narrative_ontology:affects_constraint/2,
    narrative_ontology:coordination_type/2,
    constraint_indexing:constraint_classification/3,
    constraint_indexing:directionality_override/3,
    narrative_ontology:omega_variable/3,
    narrative_ontology:human_readable/2,
    narrative_ontology:topic_domain/2.

/* ==========================================================================
   1. NARRATIVE CONTEXT
   ========================================================================== */

/**
 * CONSTRAINT IDENTIFICATION
 *   constraint_id: crispr_genomic_rewrite_2026
 *   human_readable: CRISPR Genomic Programmability
 *   domain: technological/biological
 *
 * SUMMARY:
 *   CRISPR genomic programmability represents a fundamental expansion of
 *   human capacity to read and modify genetic code. The constraint operates
 *   as both a coordination mechanism (enabling precise disease therapy) and
 *   an extraction mechanism (concentrating access, embedding heritable
 *   choices, reinforcing genetic inequality). The same technological
 *   capability generates different structural relationships depending on the
 *   actor's position: biotech enterprises experience coordination and value
 *   capture; future generations experience irreversible modification without
 *   consent; low-resource populations experience access barriers; regulatory
 *   frameworks experience enforcement challenges; consent infrastructure
 *   experiences maturation from theater toward function; the somatic/germline
 *   distinction persists as regulatory theater despite weakening technical
 *   justification. The analysis identifies all six DR types from distinct
 *   structural perspectives, with germline editing representing pure
 *   extraction (snare) and somatic applications approaching coordination
 *   (rope), while the regulatory apparatus attempts tangled rope enforcement.
 *   Theater ratio (0.52) reflects that genetic consent and oversight
 *   mechanisms are partly functional (genuine ethical scrutiny exists) but
 *   partly performative (consent forms often fail to communicate
 *   irreversibility; genetic counseling capacity is insufficient; regulatory
 *   scope diverges across jurisdictions). The constraint's extractiveness
 *   (0.38) is moderate: significant asymmetry exists (biotech benefits,
 *   future generations bear heritable risk), but legitimate therapeutic
 *   coordination also occurs.
 *
 * KEY AGENTS:
 *   - Biotech Enterprises and Pharma: Primary beneficiary (institutional/arbitrage) — capture value from therapeutic applications, intellectual property, first-mover advantages in gene-editing markets
 *   - Future Generations: Primary victim (powerless/trapped) — subject to heritable modifications without consent; bear irreversible genetic consequences; cannot exit modified genome
 *   - Low-Resource Populations: Secondary victim (moderate/constrained) — face cost barriers to somatic therapies; excluded from early-access germline selection; experience genetic inequality reinforcement
 *   - Regulatory Frameworks (NIH, EMA, WHO, national ethics committees): Organized enforcement (organized/constrained) — maintain germline/somatic distinction and oversight; suppress enhancement pathways; constrained by enforcement capacity and jurisdictional divergence
 *   - Genetic Counseling and Informed Consent Infrastructure: Emerging coordination (organized/constrained) — building genuine consent mechanisms; currently mixed functional/performative state with sunset toward full functionality
 *   - Somatic/Germline Regulatory Distinction: Institutional theater (institutional/arbitrage) — policy category persisting despite weakening technical justification; maintains appearance of control while dual-use risks remain
 *   - Analytical Observer: Civilizational view (analytical/analytical) — risks naturalizing governance problem as immutable technological law
 */

/* ==========================================================================
   2. BASE PROPERTIES (DOMAIN PRIORS)
   ========================================================================== */

% --- Numerical metrics ---
domain_priors:base_extractiveness(crispr_genomic_rewrite_2026, 0.38).
domain_priors:suppression_score(crispr_genomic_rewrite_2026, 0.48).
domain_priors:theater_ratio(crispr_genomic_rewrite_2026, 0.52).

% --- Constraint metric facts (engine primary keys, must mirror domain_priors) ---
narrative_ontology:constraint_metric(crispr_genomic_rewrite_2026, extractiveness, 0.38).
narrative_ontology:constraint_metric(crispr_genomic_rewrite_2026, suppression_requirement, 0.48).
narrative_ontology:constraint_metric(crispr_genomic_rewrite_2026, theater_ratio, 0.52).

% --- Constraint claim ---
narrative_ontology:constraint_claim(crispr_genomic_rewrite_2026, tangled_rope).
narrative_ontology:human_readable(crispr_genomic_rewrite_2026, "CRISPR Genomic Programmability").
narrative_ontology:topic_domain(crispr_genomic_rewrite_2026, "technological/biological").

domain_priors:requires_active_enforcement(crispr_genomic_rewrite_2026).

% --- Structural relationships ---
narrative_ontology:constraint_beneficiary(crispr_genomic_rewrite_2026, biotech_enterprises).
narrative_ontology:constraint_beneficiary(crispr_genomic_rewrite_2026, agricultural_productivity_sector).
narrative_ontology:constraint_beneficiary(crispr_genomic_rewrite_2026, disease_prevention_medicine).
narrative_ontology:constraint_victim(crispr_genomic_rewrite_2026, germline_consent_boundaries).
narrative_ontology:constraint_victim(crispr_genomic_rewrite_2026, genetic_diversity_commons).
narrative_ontology:constraint_victim(crispr_genomic_rewrite_2026, equitable_access_populations).

/* ==========================================================================
   3. INDEXED CLASSIFICATIONS (P, T, E, S)
   ========================================================================== */

% PERSPECTIVE 1: FUTURE GENERATIONS (SNARE) — Cannot exit heritable modifications made via germline CRISPR editing. Inherits genetic modifications without consent or reversibility. Bears full epistemic and biological cost of off-target effects, mosaicism, and unknown long-term consequences. Maximum experienced extraction — immobilized by irreversibility across generations.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, snare,
    context(agent_power(powerless),
            time_horizon(generational),
            exit_options(trapped),
            spatial_scope(global))).

% PERSPECTIVE 2: LOW-RESOURCE POPULATIONS (TANGLED ROPE) — Constrained by cost barriers ($10,000-$100,000+ per treatment in high-income countries; often inaccessible in low-income settings) and limited regulatory oversight in certain jurisdictions. May benefit from somatic CRISPR therapies for treatable genetic diseases, but access is asymmetrically distributed. Experience both coordination (shared disease burden reduction) and extraction (genetic inequality reinforced).
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, tangled_rope,
    context(agent_power(moderate),
            time_horizon(biographical),
            exit_options(constrained),
            spatial_scope(national))).

% PERSPECTIVE 3: BIOTECH ENTERPRISES AND PHARMA (ROPE) — Primary beneficiaries. Experience CRISPR as a coordination mechanism: the tool enables precise disease targeting, reduced off-target effects vs earlier gene-editing systems, and rapid therapeutic development pathways. Have exit options (can select target genes, markets, and regulatory jurisdictions). Net beneficiary — extraction of value runs toward this actor.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, rope,
    context(agent_power(institutional),
            time_horizon(immediate),
            exit_options(arbitrage),
            spatial_scope(global))).

% PERSPECTIVE 4: GERMLINE-EDITING REGULATORY FRAMEWORK (TANGLED ROPE) — Organized oversight systems (NIH, EMA, WHO guidance, national bioethics committees) face asymmetric pressures: coordinating legitimate therapeutic development (somatic CRISPR) while suppressing heritable modifications and dual-use enhancement. Must maintain oversight despite high enforcement costs and limited enforcement capacity in many jurisdictions. Active enforcement required; suppression of enhancement pathways is significant but imperfect.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, tangled_rope,
    context(agent_power(organized),
            time_horizon(generational),
            exit_options(constrained),
            spatial_scope(global))).

% PERSPECTIVE 5: GENETIC LITERACY AND CONSENT INFRASTRUCTURE (SCAFFOLD) — Emerging frameworks (informed consent protocols, genetic counseling expansion, community benefit agreements) function as temporary coordination with a sunset. As genetic literacy increases, regulatory maturity deepens, and long-term outcome tracking accumulates, consent mechanisms transition from theater (signing consent forms without understanding reversibility) to genuine shared decision-making. Suppression is declining as transparency improves — theaters are being replaced with function.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, scaffold,
    context(agent_power(organized),
            time_horizon(generational),
            exit_options(constrained),
            spatial_scope(global))).

% PERSPECTIVE 6: SOMATIC/GERMLINE DISTINCTION AS POLICY THEATER (PITON) — The legal and regulatory distinction between somatic (non-heritable) and germline (heritable) CRISPR applications is increasingly performative. Technical barriers to maintaining this distinction are eroding: mosaicism in somatic edits can have heritable consequences; germline editing for disease prevention approaches somatic disease treatment in intent; the dual-use risk is inherent to the tool itself. The distinction persists through regulatory inertia rather than functional separation. Theater ratio is high because the policy category persists despite weakening technical justification.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, piton,
    context(agent_power(institutional),
            time_horizon(civilizational),
            exit_options(arbitrage),
            spatial_scope(global))).

% PERSPECTIVE 7: ANALYTICAL OBSERVER / THERMODYNAMIC CONSTRAINT (MOUNTAIN) — From a civilizational scope, the capacity to edit the genetic code is an immutable feature of molecular biology: once a tool for reading and modifying DNA exists, the capability cannot be uninvented. The constraint is not the existence of CRISPR but the irreversibility of heritable changes in biological systems. However, this perspective risks naturalizing what is actually a governance and equity problem.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, mountain,
    context(agent_power(analytical),
            time_horizon(civilizational),
            exit_options(analytical),
            spatial_scope(universal))).

/* ==========================================================================
   4. VALIDATION TESTS
   ========================================================================== */

:- begin_tests(crispr_genomic_rewrite_2026_tests).

test(perspectival_gap) :-
    constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, TypePowerless, context(agent_power(powerless), _, _, _)),
    constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, TypeOther, context(agent_power(moderate), _, _, _)),
    TypePowerless \= TypeOther.

test(piton_threshold) :-
    domain_priors:theater_ratio(crispr_genomic_rewrite_2026, TR),
    TR >= 0.70.

:- end_tests(crispr_genomic_rewrite_2026_tests).

/* ==========================================================================
   5. GENERATIVE COMMENTARY
   ========================================================================== */

/**
 * LOGIC RATIONALE:
 *   Extractiveness (0.38): Moderate. CRISPR enables genuine therapeutic value (disease prevention, treatment of monogenic disorders), but the capacity is unequally distributed and germline applications create heritable extraction. The value is not captured primarily through coercion (low suppression relative to some snares) but through cost barriers, jurisdictional arbitrage, and control of the selection mechanism itself. Over the interval (0-6 years), extractiveness has increased from 0.28 to 0.38 as cost barriers have widened and germline research has accelerated. Suppression (0.48): Moderate. Significant barriers to alternative genetic therapies exist, and regulatory suppression of enhancement pathways is real but imperfect. Jurisdictional divergence (China's regulatory permissiveness vs EU caution) creates enforcement gaps. Some populations have no exit from cost barriers; others have arbitrage options through cross-border travel or regulatory shopping. Suppression is not total — alternative somatic therapies exist, and germline alternatives (natural selection, adoption) remain available to those willing to bear social costs. Theater ratio (0.52): Moderate-high and increasing. Genetic consent protocols exist but often lack genuine understanding of irreversibility and long-term unknowns. Regulatory distinctions (somatic/germline) persist despite weakening technical justification. The distinction is meaningful as policy but increasingly performative as biology — mosaicism blurs boundaries; germline disease prevention approaches somatic intent; dual-use is inherent.
 *
 * PERSPECTIVAL GAP:
 *   This constraint demonstrates profound perspectival divergence driven by timespan and reversibility. The biotech enterprise sees rope: legitimate therapeutic coordination with clear value capture. Future generations see snare: irreversible modification without consent. Low-resource populations see tangled rope: some benefit from somatic therapies but constrained by cost and excluded from germline enhancement. Regulatory frameworks see tangled rope: coordinating legitimate therapy while suppressing enhancement, constrained by jurisdictional arbitrage. Consent infrastructure sees scaffold: currently mixed theater/function but maturation pathway visible (increased genetic literacy, regulatory tightening, long-term outcome tracking). The somatic/germline distinction sees piton: policy category persisting through institutional inertia despite weakening technical justification. The civilizational analytical view risks seeing mountain (unreversible biology), but the structural data reveals extraction mechanisms that are not natural laws but governance choices.
 *
 * DIRECTIONALITY LOGIC:
 *   Each perspective's d value derives from structural position relative to the extraction flow. Biotech enterprises as primary beneficiaries with arbitrage options (can select markets, targets, jurisdictions) experience low d → negative effective extraction (they benefit). Future generations as powerless, trapped agents unable to exit or modify heritable consequences experience high d → high effective extraction (they bear costs). Low-resource populations with constrained exit (cost barriers, limited geographic mobility, limited access to alternatives) experience moderate-high d → moderate effective extraction. Regulatory frameworks with organized power but constrained enforcement (limited capacity to prevent cross-border germline research) experience intermediate d. The piton classification derives from theater ratio, not from high effective extraction — the somatic/germline distinction is performative rather than functionally separating risks.
 *
 * MANDATROPHY ANALYSIS:
 *   DIAGNOSTIC: This constraint resolves mandatrophy through temporal and spatial decomposition. The 'CRISPR is technology' frame risks naturalizing what is actually a governance problem (extraction via access control, cost barriers, heritable choice concentration). The snare perspective reveals that germline applications are irreversible extraction from future agents. The rope perspective reveals legitimate therapeutic coordination. The tangled rope perspectives reveal mixed coordination-extraction at regulatory and population scales. The piton perspective reveals that the somatic/germline distinction — the primary policy tool for managing mandatrophy — is increasingly theater. The mandatrophy is resolved not by assigning a single type but by recognizing that the constraint operates across six structurally distinct domains: somatic therapy (rope to tangled rope), germline modification (snare for future generations), access equity (tangled rope for low-resource populations), regulatory enforcement (tangled rope constrained by dual-use), consent infrastructure (scaffold maturation), and policy category persistence (piton). No single classification answers 'what is CRISPR?' — the presheaf over the observation site is the answer.
 */

/* ==========================================================================
   6. OMEGA VARIABLES (Ω) - IRREDUCIBLE UNCERTAINTIES
   ========================================================================== */

omega_variable(
    off_target_effect_characterization,
    'What threshold of off-target effects transforms CRISPR from therapeutic tool to mutagenic risk in germline applications?',
    'Whole-genome sequencing of CRISPR-edited embryos and long-term phenotypic tracking across generations; correlation of off-target rate with clinical outcomes',
    'If off-target rate < 0.1%: germline applications may approach somatic therapeutic safety, reducing snare classification. If rate > 1%: germline extraction classification strengthens due to inherited risk.',
    confidence_without_resolution(high)
).

narrative_ontology:omega_variable(off_target_effect_characterization, empirical, 'Off-target mutation threshold for germline safety').

omega_variable(
    cost_curve_convergence,
    'Will somatic CRISPR therapy costs fall sufficiently to reach low-income populations within 10-15 years, or will the technology remain accessible primarily in high-income jurisdictions?',
    'Historical cost curve analysis for comparable therapeutics (gene therapy, CAR-T); production scaling studies; regional pilot program outcomes',
    'If convergence occurs: tangled rope classification narrows toward rope for low-resource populations. If divergence continues: victims classification and suppression values increase; snare classification emerges at global scale.',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(cost_curve_convergence, empirical, 'Convergence of somatic CRISPR costs to low-income accessibility').

omega_variable(
    dual_use_enforcement_capacity,
    'Can germline-editing bans be meaningfully enforced globally, or is the technology fundamentally dual-use in ways that make enforcement theater?',
    'Analysis of enforcement mechanisms across jurisdictions; capacity assessment for detecting illicit germline applications; tracking of regulatory evasion attempts',
    'If enforcement is viable: scaffold and tangled rope classifications hold. If enforcement is theater: piton classification strengthens; germline suppression value should be downgraded to reflect actual capacity.',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(dual_use_enforcement_capacity, conceptual, 'Enforceability of germline-editing bans').

omega_variable(
    moral_status_consensus,
    'Will cultures converge on shared norms about which germline modifications are therapeutic vs enhancement, or will jurisdiction fragmentation persist?',
    'Survey of institutional ethics guidance across cultures; tracking of divergence/convergence in national CRISPR policies; outcome of WHO and regional regulatory harmonization efforts',
    'If convergence: regulatory framework classification as tangled rope is stable. If fragmentation: arbitrage opportunities for regulatory capture increase; extracted value shifts from biotech to jurisdictional arbitrage actors.',
    confidence_without_resolution(low)
).

narrative_ontology:omega_variable(moral_status_consensus, preference, 'Cultural consensus on therapeutic vs enhancement germline editing').


/* ==========================================================================
   7. INTEGRATION HOOKS
   ========================================================================== */

narrative_ontology:interval(crispr_genomic_rewrite_2026, 0, 6).

/* ==========================================================================
   8. TEMPORAL MEASUREMENTS (LIFECYCLE DRIFT DATA)
   ========================================================================== */

% Theater ratio over time
narrative_ontology:measurement(crispr_tr_t0, crispr_genomic_rewrite_2026, theater_ratio, 0, 0.35).
narrative_ontology:measurement(crispr_tr_t3, crispr_genomic_rewrite_2026, theater_ratio, 3, 0.48).
narrative_ontology:measurement(crispr_tr_t6, crispr_genomic_rewrite_2026, theater_ratio, 6, 0.52).

% Extraction over time
narrative_ontology:measurement(crispr_be_t0, crispr_genomic_rewrite_2026, base_extractiveness, 0, 0.28).
narrative_ontology:measurement(crispr_be_t3, crispr_genomic_rewrite_2026, base_extractiveness, 3, 0.34).
narrative_ontology:measurement(crispr_be_t6, crispr_genomic_rewrite_2026, base_extractiveness, 6, 0.38).


/* ==========================================================================
   9. BOLTZMANN & NETWORK DATA
   ========================================================================== */

narrative_ontology:coordination_type(crispr_genomic_rewrite_2026, resource_allocation).
narrative_ontology:affects_constraint(crispr_genomic_rewrite_2026, germline_enhancement_dual_use).
narrative_ontology:affects_constraint(crispr_genomic_rewrite_2026, genetic_equity_access_barrier).
narrative_ontology:affects_constraint(crispr_genomic_rewrite_2026, heritable_modification_consent_boundary).

% DUAL FORMULATION NOTE:
% CRISPR genomic programmability represents a constraint family with distinct ε values for different application domains. Somatic disease therapy ε ≈ 0.15-0.25 (primarily rope/scaffold). Germline enhancement ε ≈ 0.65-0.80 (primarily snare/snare). Access equity ε ≈ 0.40-0.55 (primarily tangled rope). This story captures the bundle; downstream stories decompose application-specific constraints. The network links show causal dependency: somatic therapy advances increase pressure toward germline applications; regulatory capture attempts increase if institutional enforcement weakens.

/* ==========================================================================
   10. DIRECTIONALITY OVERRIDES (v6.0, OPTIONAL)
   ========================================================================== */

constraint_indexing:directionality_override(crispr_genomic_rewrite_2026, powerful, 0.35).

/* ==========================================================================
   END OF CONSTRAINT STORY
   ========================================================================== */
